Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT February 26, 2024
Pivotal Ph 3 Trial of Trilaciclib to continue in metastatic TNBC Following Interim Analysis by IDMC February 26, 2024
Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 26, 2024
Ph 3 PRESERVE 2 trial of Cosela in mTNBC to continue to final analysis following IDMC recommendation February 26, 2024
REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer initiated February 26, 2024
First Patient Dosed in Ph 1b/2 Trial of Samuraciclib + Vepdegestrant in Patients with Advanced Breast Cancer February 26, 2024
Dragonfly Announces Clinical Collaboration Exploring Combinations of DF1001 HER-2 TriNKET® with Trodelvy® in two Cancer Indications February 26, 2024
Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 10, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 6, 2024
Unprecedented Preliminary Survival and Clinical Benefit reported in Antibody-Drug Conjugate (ADC) Refractory Patient Subset treated with Bria-IMT™ regimen January 4, 2024
First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer December 19, 2023
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers December 11, 2023
Menarini Group and SciClone Pharmaceuticals to Develop and Commercialize ORSERDU® (Elacestrant) in China in Advanced or Metastatic Breast Cancer December 11, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor December 11, 2023
First Patient Enrolled in Ph 2 Study of BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu December 11, 2023
Interim Data from Ph 1b Trial of Vepdegestrant in Combination with IBRANCE Announced December 11, 2023
